Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure

[1]  J. Petrozzino,et al.  An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. , 2009, AIDS patient care and STDs.

[2]  D. Podzamczer,et al.  A Once-Daily Lopinavir/Ritonavir-Based Regimen Is Noninferior to Twice-Daily Dosing and Results in Similar Safety and Tolerability in Antiretroviral-Naive Subjects Through 48 Weeks , 2009, Journal of acquired immune deficiency syndromes.

[3]  C. Boucher,et al.  HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review , 2009, AIDS.

[4]  S. Suwanagool,et al.  Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. , 2008, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[5]  C. Boucher,et al.  Novel mechanisms of HIV protease inhibitor resistance , 2008, Current opinion in HIV and AIDS.

[6]  Lynne Peeples,et al.  Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.

[7]  Philippe Flandre,et al.  Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients , 2008, AIDS.

[8]  P. Vernazza,et al.  The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial , 2007, AIDS.

[9]  Wasun Chantratita,et al.  Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Laura Galli,et al.  Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study) , 2006, AIDS.

[11]  B. Yip,et al.  Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response , 2006, AIDS.

[12]  J. Neaton,et al.  CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. , 2005, The Journal of infectious diseases.

[13]  C. Hicks,et al.  Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. , 2005, The Journal of antimicrobial chemotherapy.

[14]  S. Umemura,et al.  Different clinical and coronary angiographic findings according to ratios of total cholesterol to high-density lipoprotein cholesterol during the acute phase of myocardial infarction. , 2004, Journal of cardiology.

[15]  J. Buring,et al.  Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men. , 2004, American heart journal.

[16]  D. Burger,et al.  Simultaneous Determination of the HIV Drugs Indinavir, Amprenavir, Saquinavir, Ritonavir, Lopinavir, Nelfinavir, the Nelfinavir Hydroxymetabolite M8, and Nevirapine in Human Plasma by Reversed-Phase High-Performance Liquid Chromatography , 2003, Therapeutic drug monitoring.

[17]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[18]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[19]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[20]  J. Gatell,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. , 2006, JAMA.

[21]  S. Knobler,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[22]  P. Ghys,et al.  © Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2004 , 2004 .

[23]  C. Loveday,et al.  Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection , 2000 .

[24]  Robert T. Schooley,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). , 1997, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation.

[25]  S. Hammer,et al.  Antiretroviral Drug Resistance Testing in Adult Hiv-1 Infection: 2008 Recommendations of an International Aids Society–usa Panel , 2022 .